文献速递冠心病血脂与心血管预防

低剂量秋水仙碱对慢性冠心病冠脉周围炎症及斑块成分的影响:LoDoCo2 试验亚分析

Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial.
PubMed 文献 · Heart · 2025-11-12

该研究为 LoDoCo2 试验的横断面全国亚分析,对 151 名慢性冠心病患者随机接受秋水仙碱或安慰剂治疗中位 28.2 个月后行 CT 血管成像。结果显示两组冠脉周围脂肪组织衰减无显著差异,但秋水仙碱组钙化斑块体积和负荷更高,低衰减斑块负荷在低强度他汀使用者中更低。

要点

  • 低剂量秋水仙碱未显著改变冠脉周围脂肪组织衰减。
  • 秋水仙碱组钙化斑块体积和负荷更高,致密钙化斑块体积也更高。
  • 低衰减斑块负荷降低仅见于低强度他汀使用者,与他汀强度存在交互作用。

核心结论

  • 低剂量秋水仙碱未显著改变冠脉周围炎症,但与非钙化斑块向钙化斑块转变相关,提示斑块稳定。

研究设计与样本

  • LoDoCo2 试验的横断面全国亚分析,共纳入 151 名慢性冠心病患者,随机接受秋水仙碱或安慰剂,中位治疗 28.2 个月后行 CT 血管成像。

主要发现

  • 冠脉周围脂肪组织衰减中位数在秋水仙碱组为 -79.5 HU,安慰剂组为 -78.7 HU,差异无统计学意义(p=0.236)。
  • 秋水仙碱组钙化斑块体积为 169.6 mm3,安慰剂组为 113.1 mm3(p=0.041);钙化斑块负荷分别为 9.6% 和 7.0%(p=0.035)。
  • 秋水仙碱组致密钙化斑块体积为 192.8 mm3,安慰剂组为 144.3 mm3(p=0.048),且独立于他汀治疗。
  • 在低强度他汀使用者中,秋水仙碱与更低低衰减斑块负荷相关,而高强度他汀使用者中未见此关联(交互作用 p=0.037)。

临床怎么用

  • 低剂量秋水仙碱可能通过促进斑块钙化而非减轻冠脉周围炎症来降低心血管事件风险。
  • 对于慢性冠心病患者,秋水仙碱的获益可能部分体现在斑块成分稳定上。

局限性

  • 本研究为横断面亚分析,样本量较小(151 例),无法确定因果关系。
  • CT 血管成像仅在部分随机参与者中进行,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose colchicine (0.5 mg once daily) reduces the risk of major cardiovascular events in coronary disease, but its mechanism of action is not yet fully understood. We investigated whether low-dose colchicine is associated with changes in pericoronary inflammation and plaque composition in patients with chronic coronary disease. METHODS: We performed a cross-sectional, nationwide, subanalysis of the Low-Dose Colchicine 2 Trial (LoDoCo2, n=5522). CT angiography studies were performed in 151 participants randomised to colchicine or placebo after a median treatment duration of 28.2 months. Pericoronary adipose tissue (PCAT) attenuation measurements around proximal coronary artery segments and quantitative plaque analysis for the entire coronary tree were performed using artificial intelligence-enabled plaque analysis software. RESULTS: Median PCAT attenuation was not significantly different between the two groups (-79.5 Hounsfield units (HU) for colchicine versus -78.7 HU for placebo, p=0.236). Participants assigned to colchicine had a higher volume (169.6 mm3 vs 113.1 mm3, p=0.041) and burden (9.6% vs 7.0%, p=0.035) of calcified plaque, and higher volume of dense calcified plaque (192.8 mm3 vs 144.3 mm3, p=0.048) compared with placebo, independent of statin therapy. Colchicine treatment was associated with a lower burden of low-attenuation plaque in participants on a low-intensity statin, but not in those on a high-intensity statin (pinteraction=0.037). CONCLUSIONS: Pericoronary inflammation did not differ among participants who received low-dose colchicine compared with placebo. Low-dose colchicine was associated with a higher volume of calcified plaque, particularly dense calcified plaque, which is considered a feature of plaque stability.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Fiolet ATL, Lin A, Kwiecinski J, et al. Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial. Heart. 2025. PMID: 40393691. doi:10.1136/heartjnl-2024-325527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。